within Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M02A_TopicalProductsForJointAndMuscularPain.M02AA29_Esflurbiprofen;

model Esflurbiprofen
  extends Pharmacolibrary.Drugs.ATC.M.M02AA29;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>M02AA29</td></tr><td>route:</td><td>topical</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Esflurbiprofen is the S-enantiomer of flurbiprofen, a nonsteroidal anti-inflammatory drug (NSAID) that exhibits analgesic and anti-inflammatory properties primarily through inhibition of cyclooxygenase (COX) enzymes. Esflurbiprofen has been investigated as a topical agent for musculoskeletal and joint pain, but it is not widely approved as a separate medication in most countries, with its parent racemate (flurbiprofen) being used more commonly.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are not directly available in peer-reviewed literature for esflurbiprofen itself. Estimates below are inferred based on typical topical NSAID characteristics and existing flurbiprofen data.</p><h4>References</h4><ol><li><p>Amemiya, M, et al., &amp; Koga, H (2021). Comparison of tissue pharmacokinetics of esflurbiprofen plaster with flurbiprofen tablets in patients with knee osteoarthritis: A multicenter randomized controlled trial. <i>Biopharmaceutics &amp; drug disposition</i> 42(9) 418â€“426. DOI:<a href=&quot;https://doi.org/10.1002/bdd.2302&quot;>10.1002/bdd.2302</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34529839/&quot;>https://pubmed.ncbi.nlm.nih.gov/34529839</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Esflurbiprofen;
